An evaluation of statistical approaches to postmarketing surveillance

被引:27
作者
Ding, Yuxin [1 ]
Markatou, Marianthi [1 ]
Ball, Robert [2 ]
机构
[1] SUNY Buffalo, Dept Biostat, Buffalo, NY 14214 USA
[2] US FDA, Off Surveillance & Epidemiol, Ctr Drug Evaluat & Res, Silver Spring, MD USA
关键词
adverse event identification; likelihood ratio test; pharmacovigilance; postmarketing surveillance; signal detection; LARGE FREQUENCY TABLES; FALSE DISCOVERY RATE; SIGNAL-DETECTION METHODS; REJECTIVE MULTIPLE TEST; SAFETY DATA; DRUG; FDA; STRATEGIES; DESIGN; DISPROPORTIONALITY;
D O I
10.1002/sim.8447
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Safety of medical products presents a serious concern worldwide. Surveillance systems of postmarket medical products have been established for continual monitoring of adverse events (AEs) in many countries, and the proliferation of electronic health record systems further facilitates continual monitoring for AEs. We review existing statistical methods for signal detection that are mostly in use in postmarketing safety surveillance of spontaneously reported AEs and we study their performance characteristics by simulation. We compare those with the likelihood ratio test (LRT) method (appropriately modified for use in pharmacovigilance) and use three different methods to generate data (AE based, drug based, and a modification of the method of Ahmed et al). Performance metrics include type I error, power, sensitivity, and false discovery rate, among others. The results show superior performance of the LRT method in almost all simulation experiments. An application to the FDA Adverse Event Reporting System database is illustrated using rhabdomyolysis-related preferred terms reported to FDA during the third-quarter of 2014 to the first-quarter of 2017 for statin drugs. We present a critical discussion and recommendations for use of these methods.
引用
收藏
页码:845 / 874
页数:30
相关论文
共 56 条
[1]   Pharmacovigilance Data Mining With Methods Based on False Discovery Rates: A Comparative Simulation Study [J].
Ahmed, I. ;
Thiessard, F. ;
Miremont-Salame, G. ;
Begaud, B. ;
Tubert-Bitter, P. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 88 (04) :492-498
[2]   False Discovery Rate Estimation for Frequentist Pharmacovigilance Signal Detection Methods [J].
Ahmed, I. ;
Dalmasso, C. ;
Haramburu, F. ;
Thiessard, F. ;
Broet, P. ;
Tubert-Bitter, P. .
BIOMETRICS, 2010, 66 (01) :301-309
[3]  
Ahmed I, 2016, PHVID R PACKAGE PHAR
[4]   Bayesian pharmacovigilance signal detection methods revisited in a multiple comparison setting [J].
Ahmed, Ismail ;
Haramburu, Francoise ;
Fourrier-Reglat, Annie ;
Thiessard, Frantz ;
Kreft-Jais, Carmen ;
Miremont-Salame, Ghada ;
Begaud, Bernard ;
Tubert-Bitter, Pascale .
STATISTICS IN MEDICINE, 2009, 28 (13) :1774-1792
[5]  
[Anonymous], 1986, DENSITY ESTIMATION
[6]  
[Anonymous], 2014, INFORM DRUG CLASS ST
[7]   The FDA's Sentinel Initiative-A Comprehensive Approach to Medical Product Surveillance [J].
Ball, R. ;
Robb, M. ;
Anderson, S. A. ;
Dal Pan, G. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2016, 99 (03) :265-268
[8]   A Bayesian neural network method for adverse drug reaction signal generation [J].
Bate, A ;
Lindquist, M ;
Edwards, IR ;
Olsson, S ;
Orre, R ;
Lansner, A ;
De Freitas, RM .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 54 (04) :315-321
[9]  
Benjamini Y, 2001, ANN STAT, V29, P1165
[10]   CONTROLLING THE FALSE DISCOVERY RATE - A PRACTICAL AND POWERFUL APPROACH TO MULTIPLE TESTING [J].
BENJAMINI, Y ;
HOCHBERG, Y .
JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES B-STATISTICAL METHODOLOGY, 1995, 57 (01) :289-300